Importantly, CD151 appears to be a key player in maintenance of tumor-initiating cells in breast, prostate, and pancreatic cancers, that is, CSCs, as CD151-null/deficient ER+ tumor cells seem unable to sustain the population under in vitro culture [28,37,65,93]. Here, CD151 is linked to pancreatic neoplasm.